{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T19:13:03Z","timestamp":1769281983855,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,4]],"date-time":"2013-05-04T00:00:00Z","timestamp":1367625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/2050-6511-14-27","type":"journal-article","created":{"date-parts":[[2013,5,5]],"date-time":"2013-05-05T00:14:54Z","timestamp":1367712894000},"source":"Crossref","is-referenced-by-count":23,"title":["Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature"],"prefix":"10.1186","volume":"14","author":[{"given":"Maria AP","family":"Martins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano MM","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana F","family":"Sales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandack","family":"Nobre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoel OC","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio LP","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,4]]},"reference":[{"key":"136_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1183\/09031936.00073611","volume":"38","author":"D Falzon","year":"2011","unstructured":"Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011, 38: 516-528. 10.1183\/09031936.00073611.","journal-title":"Eur Respir J"},{"key":"136_CR2","volume-title":"Toman\u2019s tuberculosis: case detection, treatment, and monitoring","author":"World Health Organization","year":"2004","unstructured":"World Health Organization: Toman\u2019s tuberculosis: case detection, treatment, and monitoring. 2004, Geneva: World Health Organization"},{"key":"136_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1055\/s-2004-829505","volume":"25","author":"N Bock","year":"2004","unstructured":"Bock N, Reichman LB: Tuberculosis and HIV\/AIDS: epidemiological and clinical aspects (world perspective). Semin Respir Crit Care Med. 2004, 25: 337-344. 10.1055\/s-2004-829505.","journal-title":"Semin Respir Crit Care Med"},{"key":"136_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1471-2334-8-136","volume":"8","author":"W Manosuthi","year":"2008","unstructured":"Manosuthi W, Tantanathip P, Prasithisirikul W, Likanonsakul S, Sungkanuparph S: Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with\/without prior co-administration of rifampicin: a 144-week prospective study. BMC Infect Dis. 2008, 8: 136-10.1186\/1471-2334-8-136.","journal-title":"BMC Infect Dis"},{"key":"136_CR5","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1086\/322671","volume":"33","author":"S Rajagopalan","year":"2001","unstructured":"Rajagopalan S: Tuberculosis and aging: a global health problem. Clin Infect Dis. 2001, 33: 1034-1039. 10.1086\/322671.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"136_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S0213-005X(11)70014-3","volume":"29","author":"CM Santin","year":"2011","unstructured":"Santin CM, Navas EE: Tuberculosis in special populations. Enferm Infecc Microbiol Clin. 2011, 29 (Suppl 1): 20-25.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"136_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/j.1532-5415.2005.53112.x","volume":"53","author":"C Zhan","year":"2005","unstructured":"Zhan C, Correa-de-Araujo R, Bierman AS, Sangl J, Miller MR, Wickizer SW: Suboptimal prescribing in elderly outpatients: potentially harmful drug-drug and drug-disease combinations. J Am Geriatr Soc. 2005, 53: 262-267. 10.1111\/j.1532-5415.2005.53112.x.","journal-title":"J Am Geriatr Soc"},{"key":"136_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","volume":"335","author":"AM Baciewicz","year":"2008","unstructured":"Baciewicz AM, Chrisman CR, Finch CK, Self TH: Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008, 335: 126-136. 10.1097\/MAJ.0b013e31814a586a.","journal-title":"Am J Med Sci"},{"key":"136_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00002018-200225020-00005","volume":"25","author":"WW Yew","year":"2002","unstructured":"Yew WW: Clinically significant interactions with drugs used in the treatment of tuberculosis. Drug Saf. 2002, 25: 111-133. 10.2165\/00002018-200225020-00005.","journal-title":"Drug Saf"},{"key":"136_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00228-011-1086-4","volume":"67","author":"MA Martins","year":"2011","unstructured":"Martins MA, Carlos PP, Ribeiro DD, Nobre VA, Cesar CC, Rocha MO: Warfarin drug interactions: a comparative evaluation of the lists provided by five information sources. Eur J Clin Pharmacol. 2011, 67: 1301-1308. 10.1007\/s00228-011-1086-4.","journal-title":"Eur J Clin Pharmacol"},{"key":"136_CR11","doi-asserted-by":"publisher","first-page":"e44S","DOI":"10.1378\/chest.11-2292","volume":"141","author":"W Ageno","year":"2012","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G: Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141: e44S-e88S. 10.1378\/chest.11-2292.","journal-title":"Chest"},{"key":"136_CR12","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1097\/00007611-198810000-00024","volume":"81","author":"S Almog","year":"1988","unstructured":"Almog S, Martinowitz U, Halkin H, Bank HZ, Farfel Z: Complex interaction of rifampin and warfarin. South Med J. 1988, 81: 1304-1306. 10.1097\/00007611-198810000-00024.","journal-title":"South Med J"},{"key":"136_CR13","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1097\/00007611-199612000-00014","volume":"89","author":"PR Casner","year":"1996","unstructured":"Casner PR: Inability to attain oral anticoagulation: warfarin-rifampin interaction revisited. South Med J. 1996, 89: 1200-1203. 10.1097\/00007611-199612000-00014.","journal-title":"South Med J"},{"key":"136_CR14","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/0003-4819-82-2-224","volume":"82","author":"JA Romankiewicz","year":"1975","unstructured":"Romankiewicz JA, Ehrman M: Rifampin and warfarin: a drug interaction. Ann Intern Med. 1975, 82: 224-225. 10.7326\/0003-4819-82-2-224.","journal-title":"Ann Intern Med"},{"key":"136_CR15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1378\/chest.67.4.490","volume":"67","author":"TH Self","year":"1975","unstructured":"Self TH, Mann RB: Interaction of rifampin and warfarin. Chest. 1975, 67: 490-491. 10.1378\/chest.67.4.490.","journal-title":"Chest"},{"key":"136_CR16","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1592\/phco.21.15.1240.33897","volume":"21","author":"CR Lee","year":"2001","unstructured":"Lee CR, Thrasher KA: Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy. 2001, 21: 1240-1246. 10.1592\/phco.21.15.1240.33897.","journal-title":"Pharmacotherapy"},{"key":"136_CR17","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/0091270009353030","volume":"50","author":"KC Krajewski","year":"2010","unstructured":"Krajewski KC: Inability to achieve a therapeutic INR value while on concurrent warfarin and rifampin. J Clin Pharmacol. 2010, 50: 710-713. 10.1177\/0091270009353030.","journal-title":"J Clin Pharmacol"},{"key":"136_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.0889-7204.2007.05782.x","volume":"22","author":"KY Kim","year":"2007","unstructured":"Kim KY, Epplen K, Foruhari F, Alexandropoulos H: Update on the interaction of rifampin and warfarin. Prog Cardiovasc Nurs. 2007, 22: 97-100. 10.1111\/j.0889-7204.2007.05782.x.","journal-title":"Prog Cardiovasc Nurs"},{"key":"136_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/clpt.1987.168","volume":"42","author":"LD Heimark","year":"1987","unstructured":"Heimark LD, Gibaldi M, Trager WF, O\u2019Reilly RA, Goulart DA: The mechanism of the warfarin-rifampin drug interaction in humans. Clin Pharmacol Ther. 1987, 42: 388-394. 10.1038\/clpt.1987.168.","journal-title":"Clin Pharmacol Ther"},{"key":"136_CR20","doi-asserted-by":"publisher","first-page":"506","DOI":"10.7326\/0003-4819-83-4-506","volume":"83","author":"RA O\u2019Reilly","year":"1975","unstructured":"O\u2019Reilly RA: Interaction of chronic daily warfarin therapy and rifampin. Ann Intern Med. 1975, 83: 506-508. 10.7326\/0003-4819-83-4-506.","journal-title":"Ann Intern Med"},{"key":"136_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.7326\/0003-4819-81-3-337","volume":"81","author":"RA O\u2019Reilly","year":"1974","unstructured":"O\u2019Reilly RA: Interaction of sodium warfarin and rifampin. Studies in man. Ann Intern Med. 1974, 81: 337-340. 10.7326\/0003-4819-81-3-337.","journal-title":"Studies in man. Ann Intern Med"},{"key":"136_CR22","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/pds.1399","volume":"16","author":"WN Kelly","year":"2007","unstructured":"Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards IR, Fernandez AM: Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf. 2007, 16: 581-587. 10.1002\/pds.1399.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"136_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-245. 10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"136_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn JR, Hansten PD, Chan LN: Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007, 41: 674-680. 10.1345\/aph.1H423.","journal-title":"Ann Pharmacother"},{"key":"136_CR25","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2165\/00003088-200847100-00004","volume":"47","author":"Y Ohno","year":"2008","unstructured":"Ohno Y, Hisaka A, Ueno M, Suzuki H: General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet. 2008, 47: 669-680. 10.2165\/00003088-200847100-00004.","journal-title":"Clin Pharmacokinet"},{"key":"136_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.revmed.2009.07.009","volume":"31","author":"D Leveque","year":"2010","unstructured":"Leveque D, Lemachatti J, Nivoix Y, Coliat P, Santucci R, Ubeaud-Sequier G: Mechanisms of pharmacokinetic drug-drug interactions. Rev Med Interne. 2010, 31: 170-179. 10.1016\/j.revmed.2009.07.009.","journal-title":"Rev Med Interne"},{"key":"136_CR27","volume-title":"Drug interactions analysis & management","author":"PD Hansten","year":"2010","unstructured":"Hansten PD, Horn JR: Drug interactions analysis & management. 2010, Saint Louis: Wolters Kluwer"},{"key":"136_CR28","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1001\/jama.1977.03280210069029","volume":"238","author":"AR Rosenthal","year":"1977","unstructured":"Rosenthal AR, Self TH, Baker ED, Linden RA: Interaction of isoniazid and warfarin. JAMA. 1977, 238: 2177-10.1001\/jama.1977.03280210069029.","journal-title":"JAMA"},{"key":"136_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1254\/jphs.FP0040296","volume":"96","author":"Y Nishimura","year":"2004","unstructured":"Nishimura Y, Kurata N, Sakurai E, Yasuhara H: Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci. 2004, 96: 293-300. 10.1254\/jphs.FP0040296.","journal-title":"J Pharmacol Sci"},{"key":"136_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","volume":"29","author":"SF Zhou","year":"2007","unstructured":"Zhou SF, Xue CC, Yu XQ, Li C, Wang G: Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007, 29: 687-710. 10.1097\/FTD.0b013e31815c16f5.","journal-title":"Ther Drug Monit"},{"key":"136_CR31","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood.V44.6.771.771","volume":"44","author":"PT Otis","year":"1974","unstructured":"Otis PT, Feinstein DI, Rapaport SI, Patch MJ: An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood. 1974, 44: 771-781.","journal-title":"Blood"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2050-6511-14-27\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-27","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2050-6511-14-27.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,26]],"date-time":"2020-07-26T09:47:36Z","timestamp":1595756856000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/2050-6511-14-27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,4]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["136"],"URL":"https:\/\/doi.org\/10.1186\/2050-6511-14-27","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,4]]},"article-number":"27"}}